王翕田

【摘要】 目的：研究多西他賽與奈達(dá)鉑聯(lián)合治療晚期非小細(xì)胞肺癌的作用。方法：選擇2015年1月-2017年12月筆者所在醫(yī)院收治的130例晚期非小細(xì)胞肺癌患者作為研究對象，隨機(jī)均分為對照組與觀察組，每組65例。兩組均根據(jù)自身情況實(shí)施抗過敏治療及止吐治療，對照組于此基礎(chǔ)上給予多西他賽治療，觀察組于多西他賽治療基礎(chǔ)上聯(lián)合奈達(dá)鉑治療。比較兩組平均生存時(shí)間、治療效果、并發(fā)癥發(fā)生情況。結(jié)果：觀察組治療總有效率為95.38%，高于對照組的72.31%，且觀察組生存平均時(shí)間長于對照組，觀察組并發(fā)癥發(fā)生率為3.08%，低于對照組的29.23%，兩組差異均有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論：多西他賽聯(lián)合奈達(dá)鉑是一種科學(xué)有效的治療方案，對晚期非小細(xì)胞肺癌控制病情、延長壽命具有重要意義。

【關(guān)鍵詞】 晚期非小細(xì)胞肺癌; 臨床效果; 多西他賽; 奈達(dá)鉑

doi：10.14033/j.cnki.cfmr.2019.19.054 文獻(xiàn)標(biāo)識碼 B 文章編號 1674-6805（2019）19-0-02

Efficacy of Docetaxel Combined with Nedaplatin in Treatment of Advanced Non-small Cell Lung Cancer/WANG Xitian.//Chinese and Foreign Medical Research，2019，17（19）：-121

【Abstract】 Objective：To study the effect of Docetaxel combined with Nedaplatin in the treatment of advanced non-small cell lung cancer.Method：A total of 130 patients with advanced non-small cell lung cancer admitted to the hospital from January 2015 to December 2017 were randomly divided into control group and observation group，with 65 cases in each group.Both groups were treated with anti-allergic treatment and antiemetic treatment according to their own conditions.The control group was given Docetaxel on this basis，and the observation group was treated with Nedaplatin on the basis of docetaxel treatment.The average survival time，treatment effect，and complications of the two groups were compared.Result：After treatment，the effective rate of the observation group was 95.38%，which was much higher than 72.31% of the control group.The average survival time of the observation group was longer than that of the control group.The incidence of complications in the observation group was 3.08%，which was lower than 29.23% of the control group.There were significant differences between the two groups（P<0.05）.Conclusion：Docetaxel combined with Nedaplatin is a scientific and effective treatment for advanced non-small cell lung cancer.It is of great significance to control the disease and prolong the life span of advanced non-small cell lung cancer.

【Key words】 Advanced non-small cell lung cancer; Clinical effect; Docetaxel; Nedaplatin

First-authors address：Chuxiong Peoples Hospital，Chuxiong 675000，China

新時(shí)期，隨著人們生活水平的不斷提高，生活方式及習(xí)慣也在不斷發(fā)生變化，各大醫(yī)院對惡性腫瘤的報(bào)道逐年增多。權(quán)威數(shù)據(jù)顯示，每年肺癌的發(fā)病率在所有惡性腫瘤中占50%以上[1-2]，其中發(fā)病人群以男性居多，大部分患者均表現(xiàn)為非小細(xì)胞肺癌。此病發(fā)病較隱匿，在發(fā)病初期很難被發(fā)現(xiàn)，一旦確診即為晚期。晚期非小細(xì)胞肺癌患者已經(jīng)失去手術(shù)機(jī)會[3-4]，所以臨床多采取化療方案控制病灶，提高生活質(zhì)量。筆者為分析多西他賽與奈達(dá)鉑聯(lián)合治療價(jià)值，報(bào)道如下。

1 資料與方法

1.1 一般資料

選取2015年1月-2017年12月筆者所在醫(yī)院收治的130例晚期非小細(xì)胞肺癌患者為研究對象。納入晚期非小細(xì)胞肺癌患者，生存期均大于半年，白細(xì)胞數(shù)目均大于3.9×109/L[5-6]。